摘要
目的探讨吉非替尼靶向疗法对Ⅲ、Ⅳ期非小细胞肺癌患者的疗效以及用药安全性。方法 74例晚期(Ⅲ、Ⅳ期)非小细胞肺癌患者,按照入院顺序,前37例患者采用GP方案治疗(GP组),后37例患者采用吉非替尼治疗(吉非替尼组),对比两组住院期间的治疗效果和安全性。结果 GP组有效率为29.73%(11/37),低于吉非替尼组的37.84%(14/37),但差异无统计学意义(P>0.05);GP组控制率为48.65%(18/37),明显低于吉非替尼组的75.68%(28/37),差异具有统计学意义(P<0.05);两组口腔溃疡以及转氨酶升高差异无统计学意义(P>0.05);吉非替尼组腹泻、便秘明显高于GP组,其余毒副反应的发生率显著低于GP组,差异有统计学意义(P<0.05)。结论对于晚期非小细胞肺癌患者,采用吉非替尼靶向疗法能够保证患者在短期内获得较高的生活质量,减轻患者痛苦,且引起的毒副反应程度较轻,用药安全性相对较高。
Objective To investigate the curative effect and safety of gefitinib in targeted treatment of non small cell lung cancer in periods Ⅲ and Ⅳ. Methods A total of 74 patients with advanced（periods Ⅲ and Ⅳ） non small cell lung cancer were selected. According to their admission order, the former 37 patients were treated by GP regimen（GP group）, and the later 37 patients were treated by gefitinib（gefitinib group）. The curative effects and safety of treatment during hospital stay were compared between two groups. Results The effective rate of the GP group was 29.73%（11/37）, which was lower than 37.84%（14/37） of gefitinib group, but the difference was not statistically significant（P〉0.05）. The control rate of GP group was 48.65%（18/37）, which was significantly lower than that of gefitinib group as 75.68%（28/37）, and the difference was statistically significant（P〉0.05）. The incidences of oral ulcer and increased transaminase between the two groups had no statistically significant difference（P〈0.05）. The incidences of diarrhea and constipation in gefitinib group were higher than those in the GP group, and the incidences of the other toxic and side effects were significantly lower than those in the GP group, and the differences were statistically significant（P〈0.05）. Conclusion For patients with advanced non small cell lung cancer, the targeted treatment by gefitinib can ensure the patients＇ good life quality. It also has the advantages of pain relieving, low degree of toxic and side effect, and high safety in drug use.
出处
《中国现代药物应用》
2014年第24期6-8,共3页
Chinese Journal of Modern Drug Application
关键词
吉非替尼
非小细胞肺癌
疗效
安全性
Gefitinib
Non small cell lung cancer
Curative effect
Safety
